Determination of a prodrug of tranexamic acid in whole blood by reversed-phase liquid chromatography after pre-column derivatization with fluorescamine.
A sensitive high-performance liquid chromatographic (HPLC) method for a prodrug of tranexamic acid (KABI 2161) in whole blood is described. Since KABI 2161 is rapidly hydrolysed in whole blood the samples are collected directly into the extraction tubes and extracted immediately. After pre-column derivatization with fluorescamine the derivatives are analysed by reversed-phase liquid chromatography on a C(8)-Nucleosil column using an eluent mixture of phosphate buffer and acetonitrile (pH 3). The eluent is monitored by a fluorescence detector. Determinations as low as 10 ng ml(-1) of KABI 2161 in whole blood can be made when 0.5 ml blood is analysed. The precision of the method is 4.1% (RSD) at the 300 ng ml(-1) level and 6.9% (RSD) at the 50 ng ml(-1) level.